GlassScriptPhysician profile
Vincent Doan
NPI 1215671391
$484.44
in general payments reported to CMS, 2019-2025
10 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $79.42 · 2024: $302 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $484.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $270.81 | 2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $34.20 | 2025 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $30.66 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Ucb, INC. | $28.51 | 2025 | Bimzelx |
| Amgen INC. | $28.15 | 2023 | Repatha |
| Janssen Biotech, INC. | $21.43 | 2025 | Tremfya |
| Merck Sharp & Dohme LLC | $20.61 | 2023 | Verquvo |
| Pfizer INC. | $19.21 | 2025 | |
| Sumitomo Pharma America, INC. | $17.11 | 2024 | Gemtesa |
| Exact Sciences Corporation | $13.75 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Doan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.